Verrica Pharmaceuticals
VRCA
45 hedge funds and large institutions have $134M invested in Verrica Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 6 closing their positions.
300% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 6
67% more funds holding
Funds holding: 27 → 45 (+18)
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
0.01% more ownership
Funds ownership: 3.2% → 3.21% (+0.01%)
18% less capital invested
Capital invested by funds: $164M → $134M (-$30.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.52M |
| 2 |
BlackRock
New York
|
+$4.36M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.54M |
| 4 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
+$1.16M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.76M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
-$4.04M |
| 3 |
Goldman Sachs
New York
|
-$1M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$795K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$772K |
VRCA Hedge Fund Activity: Q3 2018 in Review
45 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q3 2018, worth a combined $134M — down 18% from $164M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new VRCA positions and 6 closed out — a net gain of 18 holders — while 9 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $4.52M. The largest seller was Fidelity Investments, cutting an estimated $7.76M.
- 45 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q3 2018, up from 27 in Q2 2018.
- Funds reported $134M of Verrica Pharmaceuticals stock for Q3 2018, down 18% quarter-over-quarter.
- 24 funds opened new Verrica Pharmaceuticals positions in Q3 2018 and 6 closed out, a net change of +18 holders.
- The largest Verrica Pharmaceuticals buyer in Q3 2018 was Vanguard Group, an estimated $4.52M added.
- The largest Verrica Pharmaceuticals seller in Q3 2018 was Fidelity Investments, an estimated $7.76M sold.
Based on aggregated 13F filings for Q3 2018.